Taro Pharmaceutical Industries Ltd Revenue Growth Rates (TARO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Taro Pharmaceutical Industries Ltd  (NYSE: TARO)
 

TARO's Revenue Growth by Quarter and Year

Taro Pharmaceutical Industries Ltd's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TARO Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December 572.95
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 572.95

TAROs Annual Revenue
Taro Pharmaceutical Industries Ltd's Revenue in the fiscal year 2023 $ 572.95 millions
Taro Pharmaceutical Industries Ltd's Revenue in the fiscal year 2022 $ 561.33 millions
Taro Pharmaceutical Industries Ltd's Revenue in the fiscal year 2021 $ 548.97 millions
Taro Pharmaceutical Industries Ltd's Revenue in the fiscal year 2020 $ 644.77 millions
Taro Pharmaceutical Industries Ltd's Revenue in the fiscal year 2019 $ 669.89 millions




TARO Revenue fourth quarter 2023 Y/Y Growth Comment
Taro Pharmaceutical Industries Ltd reported Revenue growth of 2.07% year on year in the fourth quarter 2023, to $ 572.95 millions, this is lower than Taro Pharmaceutical Industries Ltd's recent average Revenue rise of 48.21%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 142 other companies have achieved higher Revenue growth. While Taro Pharmaceutical Industries Ltd' s Revenue increase of 2.07% ranks overall at the positon no. 2376 in the fourth quarter 2023.


TARO Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December 2.07 % 2.25 % -14.86 % -3.75 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   2.07 % 2.25 % -14.86 % -

Financial Statements
Taro Pharmaceutical Industries Ltd's fourth quarter 2023 Revenue $ 572.95 millions TARO's Income Statement
Taro Pharmaceutical Industries Ltd's fourth quarter 2022 Revenue $ 561.33 millions Quarterly TARO's Income Statement


TARO Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   2.07 % 2.25 % -14.86 % -


Back to TARO Growth rate Comparisons >> Back to TARO Growth rate Comparisons >>


Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #143
Healthcare Sector #389
Overall #2376

Revenue Y/Y Growth Statistics
High Average Low
423.14 % 48.21 % -14.86 %
  (Mar 31 2018)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #143
Healthcare Sector #389
Overall #2376
Revenue Y/Y Growth Statistics
High Average Low
423.14 % 48.21 % -14.86 %
  (Mar 31 2018)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Taro Pharmaceutical Industries Ltd's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TARO's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TARO's IV. Quarter Q/Q Revenue Comment


Taro Pharmaceutical Industries Ltd's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Mar 31 2019)
Cumulative Revenue 12 Months Ending $ 572.95 $ 561.33 $ 548.97 $ 644.77 $ 669.89
Y / Y Revenue Growth (TTM) 2.07 % 2.25 % -14.86 % -3.75 % 1.21 %
Year on Year Revenue Growth Overall Ranking # 2843 # # # # 3335
Seqeuential Revenue Change (TTM) 2.07 % 2.25 % -14.86 % -3.75 % 1.21 %
Seq. Revenue Growth (TTM) Overall Ranking # 2843 # # # # 3335


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2023 period, Taro Pharmaceutical Industries Ltd's cumulative twelve months Revenue were $ 573 millions, company would post below average annual Revenue growth of 1.21% year on year, if the fiscal year would end at Mar 31 2023.
A slow-down in the Taro Pharmaceutical Industries Ltd's Revenue growth from the 661.913% growth in Mar 31 2022.

In the Healthcare sector 397 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from to 2843.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 142
Healthcare Sector # 398
Overall # 2877

Revenue TTM Y/Y Growth Statistics
High Average Low
32.69 %
 2.21 %
-24.73 %
(Mar 31 2013)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 142
Sector # 398
S&P 500 # 2877
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2023 period, Taro Pharmaceutical Industries Ltd's cumulative twelve months Revenue were $ 573 millions, company would post below average annual Revenue growth of -24.73% year on year, if the fiscal year would end at Mar 31 2023.
A slow-down in the Taro Pharmaceutical Industries Ltd's Revenue growth from the 661.913% growth in Mar 31 2022.

In the Healthcare sector 397 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from to 2843.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 142
Healthcare Sector # 398
Overall # 2877

Revenue TTM Y/Y Growth Statistics
High Average Low
32.69 %
2.21 %
-24.73 %
(Mar 31 2013)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 142
Sector # 398
S&P 500 # 2877




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TARO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2023
Teladoc Health Inc 3.58%$ 3.578 millions
Iqvia Holdings Inc 3.45%$ 3.450 millions
Procaps Group S a 3.37%$ 3.373 millions
Astrazeneca Plc3.29%$ 3.292 millions
West Pharmaceutical Services Inc 3.22%$ 3.217 millions
Dentsply Sirona Inc 2.95%$ 2.950 millions
AnTix Holdings, Inc.2.93%$ 2.926 millions
Oculis Holding Ag2.90%$ 2.899 millions
Igm Biosciences Inc 2.81%$ 2.806 millions
Becton Dickinson And Company2.62%$ 2.617 millions
Cumberland Pharmaceuticals Inc 2.51%$ 2.514 millions
Prestige Consumer Healthcare Inc 2.33%$ 2.328 millions
Sanofi2.32%$ 2.324 millions
Stablecoin Development Corporation2.31%$ 2.306 millions
Amneal Pharmaceuticals Inc 2.30%$ 2.298 millions
Nevro Corp 2.25%$ 2.252 millions
Centogene N v 2.16%$ 2.161 millions
Teleflex Incorporated2.09%$ 2.094 millions
Taro Pharmaceutical Industries Ltd2.07%$ 2.070 millions
Standard Biotools Inc 2.05%$ 2.050 millions
Phibro Animal Health Corporation2.03%$ 2.032 millions
Icu Medical Inc1.94%$ 1.940 millions
Koninklijke Philips Nv1.92%$ 1.918 millions
Akebia Therapeutics Inc 1.84%$ 1.838 millions
Accelerate Diagnostics Inc 1.82%$ 1.816 millions
Atrion Corporation1.70%$ 1.701 millions
Amedisys Inc1.55%$ 1.552 millions
Abbott Laboratories1.49%$ 1.486 millions
Procyon Corporation1.36%$ 1.361 millions
Aesthetic Medical International Holdings Group Limited1.32%$ 1.322 millions


About Taro Pharmaceutical Industries Ltd Revenue Growth Rates (TARO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Taro Pharmaceutical Industries Ltd (CIK 906338).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-23-030778
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Taro Pharmaceutical Industries Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.